Syndax Pharmaceuticals (SNDX) Stock Rating Lowered by ValuEngine

ValuEngine cut shares of Syndax Pharmaceuticals (NASDAQ:SNDX) from a hold rating to a sell rating in a report published on Monday, February 4th.

Several other equities analysts also recently commented on SNDX. Nomura decreased their price target on shares of Syndax Pharmaceuticals from $22.00 to $12.00 and set a buy rating on the stock in a research note on Tuesday, December 18th. Robert W. Baird assumed coverage on shares of Syndax Pharmaceuticals in a research note on Friday, January 4th. They issued an outperform rating on the stock. Zacks Investment Research upgraded shares of Syndax Pharmaceuticals from a hold rating to a buy rating and set a $4.50 price target on the stock in a research note on Tuesday, January 1st. HC Wainwright reduced their price objective on shares of Syndax Pharmaceuticals to $23.00 and set a buy rating on the stock in a research note on Friday, October 26th. Finally, Citigroup reduced their price objective on shares of Syndax Pharmaceuticals from $15.00 to $12.00 and set a buy rating on the stock in a research note on Thursday, October 11th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the company’s stock. The stock has an average rating of Hold and a consensus price target of $16.25.

Shares of SNDX opened at $6.34 on Monday. The stock has a market capitalization of $156.72 million, a PE ratio of -2.19 and a beta of 2.38. Syndax Pharmaceuticals has a fifty-two week low of $3.39 and a fifty-two week high of $15.20.

Several hedge funds have recently bought and sold shares of SNDX. Paloma Partners Management Co bought a new position in Syndax Pharmaceuticals in the 4th quarter valued at approximately $56,000. Squarepoint Ops LLC raised its holdings in Syndax Pharmaceuticals by 51.3% in the 4th quarter. Squarepoint Ops LLC now owns 18,601 shares of the company’s stock valued at $83,000 after buying an additional 6,303 shares during the last quarter. Rhumbline Advisers raised its holdings in Syndax Pharmaceuticals by 38.1% in the 4th quarter. Rhumbline Advisers now owns 19,410 shares of the company’s stock valued at $86,000 after buying an additional 5,350 shares during the last quarter. Raymond James & Associates bought a new position in Syndax Pharmaceuticals in the 4th quarter valued at approximately $98,000. Finally, Claraphi Advisory Network LLC bought a new position in Syndax Pharmaceuticals in the 3rd quarter valued at approximately $129,000. 61.41% of the stock is owned by hedge funds and other institutional investors.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapies for various cancer indications. The company's lead product candidate is Entinostat, which is in Phase 3 clinical trial for the treatment of hormone receptor positive or HR+, human epidermal growth factor receptor 2 negative or HER2-, and breast cancer; and Phase 1b/2 clinical trial.

Read More: What is a Backdoor Roth IRA?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Syndax Pharmaceuticals (NASDAQ:SNDX)

Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.